Genmab and seagen announce that tivdak® (tisotumab vedotin-tftv) met its primary endpoint of improved overall survival in patients with recurrent or metastatic cervical cancer compared to chemotherapy

Company announcement phase 3 innovatv 301 confirmatory trial met its primary endpoint of improved overall survival ( os) at prede termined , independent interim analysis t rial results to be submitted for presentation at a future medical meeting genmab and seagen to engage in discussions with regulatory authorities copenhagen , denmark , and bothell, wash. ; september 4 , 20 23 – genmab a/s ( nasdaq: gmab ) and seagen inc. (nasdaq: sgen) announced today that the phase 3 innovatv 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received tivdak® (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (os).
SGEN Ratings Summary
SGEN Quant Ranking